SCHEMBL2811212

SCHEMBL2811212

COCCCOc1cc(C)ccc1C=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
USP2 O75604 2/20 0.46
ALDH1A1 P00352 8/20 0.44
L3MBTL1 Q9Y468 8/20 0.44
HPGD P15428 6/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
HTT P42858 4/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TSHR P16473 1/20 0.43
MAPT P10636 6/20 0.42
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
CYP2C9 P11712 3/20 0.42
CYP2C19 P33261 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 1/20 0.42
LMNA P02545 2/20 0.42
L3MBTL4 Q8NA19 1/20 0.41
L3MBTL3 Q96JM7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22160259 0.84 FDPS (0.57) ALDH1A1L3MBTL1HPGDSMN1; SMN2HTT
SCHEMBL8709785 0.83 ALDH1A1 (0.43) KDM4EALDH1A1L3MBTL1HPGDSMN1; SMN2
SCHEMBL28646030 0.83 ALDH1A1 (0.47) KDM4EALDH1A1L3MBTL1HPGDSMN1; SMN2
SCHEMBL2810260 0.80 ALDH1A1 (0.71) KDM4EALDH1A1L3MBTL1HPGDSMN1; SMN2
SCHEMBL1748693 0.80 LMNA (0.51) KDM4EALDH1A1L3MBTL1HPGDSMN1; SMN2
SCHEMBL17821746 0.79 ALDH1A1 (0.65) KDM4EALDH1A1L3MBTL1HPGDSMN1; SMN2
SCHEMBL22090766 0.79 KDM4E (0.45) KDM4EUSP2ALDH1A1L3MBTL1HPGD
SCHEMBL3488752 0.79 TSHR (0.46) KDM4EALDH1A1HPGDHTTTSHR
SCHEMBL7395816 0.78 ALDH1A1 (0.54) KDM4EALDH1A1L3MBTL1HPGDSMN1; SMN2
SCHEMBL3488798 0.78 ALDH1A1 (0.39) KDM4EUSP2ALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362040-B2 4-phenylpiperidine derivatives as renin inhibitors NOVARTIS AG (CH) 2013-01-29 US disclosed
US-20100240679-A1 4-Phenylpiperidine Derivatives as Renin Inhibitors NOVARTIS AG (CH) 2010-09-23 US disclosed
US-7754727-B2 4-phenylpiperidine derivatives as renin inhibitors NOVARTIS AG (CH) 2010-07-13 US disclosed
EP-1689712-B1 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS NOVARTIS AG (CH) 2009-08-19 EP disclosed
US-20080269255-A1 4-Phenylpiperidine Derivatives as Renin Inhibitors NOVARTIS AG (CH) 2008-10-30 US disclosed
US-20070078164-A1 4-Phenylpiperidine derivatives as renin inhibitors SEDRANI RICHARD 2007-04-05 US disclosed
EP-1689712-A1 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS Novartis AG (CH) 2006-08-16 EP disclosed
WO-2005051911-A1 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS NOVARTIS AG (CH) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269255-A1 4-Phenylpiperidine Derivatives as Renin Inhibitors REN, AGTR1, ACE KDM4E 3162/4885USP2 4023/4885ALDH1A1 417/4885
US-20100240679-A1 4-Phenylpiperidine Derivatives as Renin Inhibitors REN, AGTR1, ACE KDM4E 3091/4885USP2 3902/4885ALDH1A1 466/4885
US-20070078164-A1 4-Phenylpiperidine derivatives as renin inhibitors REN, AGTR1, ACE KDM4E 3091/4885USP2 3902/4885ALDH1A1 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.